Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MRJEG
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
REGN5093-M114
|
|||||
| Synonyms |
METxMET ADC - Regeneron Pharmaceuticals; REGN5093M114; REGN 5093 M114
Click to Show/Hide
|
|||||
| Organization |
Regeneron Pharmaceuticals, Inc.
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Indication |
In total 1 Indication(s)
Non-small cell lung cancer [ICD11:2C25]
Phase 2
|
|||||
| Drug-to-Antibody Ratio |
3.2
|
|||||
| Structure |
|
|||||
| Antibody Name |
REGN5093
|
Antibody Info | ||||
| Antigen Name |
Hepatocyte growth factor receptor (MET)
|
Antigen Info | ||||
| Payload Name |
Maytansine derivative M24
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
M114
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.